© 2025 KUNR
Illustration of rolling hills with occasional trees and a radio tower.
Serving Northern Nevada and the Eastern Sierra
Donate
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
The threat of catastrophic funding cuts for public media looms, and while we don’t know what the U.S. Senate will do, we do know this: We need your help protecting this vital service.
Learn what you can do to support KUNR and public media today ➡️

Biogen faces a crisis after failure of Alzheimer's drug

Published December 13, 2021 at 10:40 AM PST

For the full story, click here.

Biogen has been hit hard after the failure of its drug Aduhelm.

The Massachusetts-based biotech company had high hopes in the first Alzheimer’s treatment in a generation earlier this year. But its approval and the lead-up to it are now under investigation.

Here & Now‘s Lisa Mullins talks with Damian Garde, a reporter with our partners at STAT, the health and medicine publication, about an in-depth report he wrote with Adam Feuerstein.

This article was originally published on WBUR.org.

Copyright 2021 NPR. To see more, visit https://www.npr.org.